Cargando…
A Breakthrough Brought about by Targeting KRAS(G12C): Nonconformity Is Punished
SIMPLE SUMMARY: KRAS is the most common oncogene in human cancers and has long been considered ‘‘undruggable’’—that is, until recently, when covalent inhibitors that selectively target KRAS(G12C) substitution were developed. The satisfactory results of multicenter clinical trials has led to the rece...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774282/ https://www.ncbi.nlm.nih.gov/pubmed/35053550 http://dx.doi.org/10.3390/cancers14020390 |